This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy (including evolving and controversial data) for adult intensive-care-unit patients will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at fraseg@mmc.org or Sandra Kane-Gill, PharmD, MSc, at kanesl@upmc.edu.
Get full access to this article
View all access options for this article.
References
1.
MichelsonA.D., CattaneoM., EikelboomJ.W.. Aspirin resistance: position paper of the working group on aspirin resistance. J Thromb Haemost.2005; 3: 1309–1311.
2.
BhattD.L.Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol.2004; 43: 1127–1129.
3.
PatronoC., CollerB., FitzGeraldG.A., HirshJ., RothG.Platelet-active drugs: the relationships among dose, effectiveness and side effects. Chest.2004; 126: 234S–264S.
4.
PedersenA.K., FitzGeraldG.A.Dose-related kinetics of aspirin. N Engl J Med.1984; 311: 1206–1211.
5.
PetersR.J., MehtaS.R., FoxK.A.. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study. Circulation.2003; 108: 1682–1687.
6.
LanzaF.L., RoyerG.L., NelsonR.S.Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med.1980; 303: 136–138.
7.
HawthorneA.B., MahidaY.R., ColeA.T., HawkeyC.J.Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol.1991; 32: 77–83.
8.
PetroskiD.Endoscopic comparison of three aspirin preparations and placebo. Clin Ther.1993; 15: 314–320.
9.
LanzaF.L., RackM.F., WagnerG.S., BalmT.K.Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level dosing of enteric-coated aspirin granules two and four times a day. Dig Dis Sci.1985; 30: 509–512.
10.
HoftiezerJ.W., SilvosoG.R., BurksM., IveyK.J.Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet.1980; 2: 609–612.
11.
de AbajoF.J., Garcia RodriguezL.A.Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulation. BMC Clin Pharmacol.2001; 1: 1.
12.
KellyJ.P., KaufmanD.W., JurgelonJ.M., SheehanJ., KoffR.S., ShapiroS.Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet.1996; 348: 1413–1416.
13.
SorensenH.T., MellemkjaerL., BlotW.J.. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroentrol.2000; 95: 2218–2224.
14.
MareeA.O., CurtinR.J., DooleyM.. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol.2005; 47: 1258–1263.
15.
AlbertsM.J., BergmanD.L., MolnerE., JovanovicB.D., UshiwataI., TeruyaJ.Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke.2004; 35: 175–178.
16.
FengD., McKennaC., MurilloJ.. Effect of aspirin dosage and enteric coating on platelet reactivity. Am J Cardiol.1997; 80: 189–193.
17.
Bode-BogerS.M., BogerR.H., SchubertM., FrolichJ.C.Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. Eur J Clin Pharmacol.1998; 54: 707–714.
